New drug trial offers hope for patients with Hard-to-Treat cancers
NCT ID NCT04478279
Summary
This study is testing a new drug called ST101 for people with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and see if the drug can help control cancers like glioblastoma, melanoma, breast cancer, and prostate cancer. The trial is for adults whose cancer has progressed despite standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University
New York, New York, 10032, United States
-
Duke University School of Medicine
Durham, North Carolina, 27708, United States
-
Edinburgh Cancer Centre
Edinburgh, EH4 2SP, United Kingdom
-
Northwestern Medicine Cancer Centers
Warrenville, Illinois, 60555, United States
-
START Midwest
Grand Rapids, Michigan, 49503, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute UK
London, W1G 6AD, United Kingdom
-
The Beaston West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Leeds
Leeds, LS9 7TF, United Kingdom
Conditions
Explore the condition pages connected to this study.